Paul LaViolette Joins Pulse Bioscience’s Board Of Directors
“We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical technology space for decades,” Duggan said. “He adds a wealth of relevant expertise to our board based on his experience successfully scaling some of the largest global cardiology franchises through driving innovative technology adoption. We are excited to work with him and benefit from his valuable insights for the years to come.”
LaViolette has significant experience as a large-scale operator at healthcare corporations, as well as an advisor to a diverse group of medical technology startups as a venture investor and board member. He is currently managing partner at SV Health Investors, investing in portfolio companies for its Medtech Convergence Fund. Before his investing career, he served in various executive capacities at Boston Scientific Corporation for 15 years, including as chief operating officer; group president, Cardiovascular; president, Cardiology; group president, Endosurgery; and president, International. Prior to Boston Scientific, he also held general management and commercial leadership positions at C.R. Bard and various marketing roles at Kendall (Medtronic).
LaViolette has experience in both chairman and director capacities for numerous private and public medical technology companies. He is currently a director for Edwards Lifesciences, chairman of the Innovation Advisory Board at Mass General Brigham, and is a director or chairman on multiple private medical device company boards.
READ MORE: Pulse Bio Wins FDA Breakthrough Nod for CellFX nsPFA to Treat AFib
LaViolette earned a bachelor’s degree in psychology from Fairfield University and an MBA from Boston College.
“I am honored to join the board at Pulse Biosciences. The company’s proprietary technology and potential to advance the clinical standard of care across numerous therapeutic categories represents a truly unique opportunity. I am thrilled to be involved with this next-generation energy source and to help the management team methodically develop the most valuable therapeutic treatments to maximize its potential for patients,” LaViolette stated. “I am excited to help the team build transformational treatments for unmet patient needs.”
Pulse Biosciences is a bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. Its proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively pursuing the development of its CellFX nsPFA technology for use in treating atrial fibrillation and in a select few other markets. Pulse Biosciences is now headquartered in Miami and maintains an office in Hayward, Calif.
link
